Development of immediate release Rupatadine fumarate 10 mg tablets: A Quality by Design (QbD) approach

An investigation into the effects of excipient particle size, blending techniques and processing parameters on the homogeneity and content uniformity of a blend containing low-dose model drug

(2017) Hamad Alyami et al.   PLoS One

Pharmaceutical excipients — quality, regulatory and biopharmaceutical considerations

(2016) David P. Elder et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation

(2015) Edina Pallagi et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Understanding Pharmaceutical Quality by Design

(2014) Lawrence X. Yu et al.   AAPS Journal

Latent variable modeling to assist the implementation of Quality-by-Design paradigms in pharmaceutical development and manufacturing: A review

(2013) Emanuele Tomba et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Dissolution Testing for Generic Drugs: An FDA Perspective

(2011) Om Anand et al.   AAPS Journal

Reactive Impurities in Excipients: Profiling, Identification and Mitigation of Drug–Excipient Incompatibility

(2011) Yongmei Wu et al.   AAPS PHARMSCITECH

Development and validation of a dissolution test with reversed-phase liquid chromatography analysis for rupatadine in tablet dosage forms

(2010) Sérgio Luiz Dalmora et al.   QUIMICA NOVA

Quality-By-Design (QbD): An Integrated Approach for Evaluation of Powder Blending Process Kinetics and Determination of Powder Blending End-point

(2009) Huiquan Wu et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Use of the Biopharmaceutical Classification System in Early Drug Development

(2008) M. Sherry Ku   AAPS Journal

Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control

(2008) Lawrence X. Yu   PHARMACEUTICAL RESEARCH